If you have ever tried to understand how pharmaceutical companies qualify for international tenders, you have probably come across two terms that seem to confuse almost everyone. One is WHO prequalification and the other is national registration. Both sound official, both involve approvals, and both matter when it comes to selling medicines internationally. But they are not the same thing, and knowing the difference can actually decide whether a company wins or loses a tender.
Starting With the Basics
National registration is exactly what it sounds like. It is the approval a pharmaceutical product receives from the drug regulatory authority of a specific country before it can be sold there. Every country has its own process, its own documentation requirements, and its own timeline. If a company wants to sell pharmaceutical products in Kenya, for example, they need approval from Kenya's regulatory body, separate from any approval they may already have in India or elsewhere.
WHO prequalification, on the other hand, works differently. It is a global evaluation done by the World Health Organisation to confirm that a product meets international quality, safety, and efficacy standards. Once a product receives this status, it becomes easier to sell across multiple countries, especially those that rely on WHO's assessment instead of running a full evaluation themselves.
This is really the heart of the WHO Prequalification vs National Registration debate. One is country-specific, and the other works on a much wider global scale.
Why This Difference Matters for Tenders
Big international tenders, especially those run by organisations like UNICEF, Global Fund, or other UN procurement bodies, often list WHO prequalification as a preferred or even mandatory requirement. This is because these agencies operate across many countries at once and need a standardised way to confirm product quality without evaluating every single item individually for each region.
If a company only has national registration in India but no WHO prequalification, they might struggle to qualify for such large international tenders, even if their product is genuinely high quality. On the other hand, some smaller or country-specific tenders may accept national registration alone, especially if the buyer is a local government body or a private hospital rather than an international organisation.
This is exactly why understanding tender requirements early on saves companies a lot of time and effort later.
The Role of Manufacturing Standards
Regardless of which approval route a company is aiming for, manufacturing quality remains the foundation of everything. This is where working with a WHO-GMP certified third-party manufacturer becomes so important. Good Manufacturing Practice certification recognised by WHO shows that a facility follows strict, internationally accepted production standards.
Having this certification does not automatically mean a company holds WHO prequalification, but it definitely puts them in a stronger position to apply for it, since manufacturing quality is one of the most heavily reviewed aspects during the prequalification process.
Why Some Companies Choose to Pursue Both
Many pharmaceutical companies do not treat this as an either-or decision. Instead, they aim to secure both WHO prequalification and national registration in key markets, since this gives them more flexibility. National registration allows access to local markets and private hospital procurement, while WHO prequalification opens doors to larger international tenders and donor-funded programmes.
This dual approach is becoming increasingly common, especially among companies exporting a wide range of pharmaceutical products, including specialised categories like dermatological skincare formulations, where multiple markets often have different registration expectations.
Challenges Companies Often Face
Getting WHO prequalification is not a quick process. It involves detailed documentation, site inspections, and thorough product evaluations, which can take a significant amount of time and resources. National registration, while usually faster, still varies a lot depending on the country, and some markets have lengthy or unpredictable approval timelines of their own.
This is why many companies plan their regulatory strategy well in advance, rather than waiting until a tender opportunity appears and then scrambling to meet requirements at the last minute.
What This Means for Buyers and Hospitals
For hospitals and procurement agencies, understanding this difference also helps in evaluating suppliers more accurately. A supplier with WHO prequalification generally signals a higher level of scrutiny and international acceptance, while national registration confirms that a product meets the specific regulatory standards of that particular country.
Depending on the nature of the tender, whether it is a local hospital contract or a large-scale international programme, buyers often look for one, the other, or sometimes both approvals before finalising a supplier.
Final Thoughts
WHO prequalification and national registration serve different purposes, but both play an important role in the pharmaceutical tender process. While national registration focuses on individual country approval, WHO prequalification offers a wider, more globally recognised stamp of quality. Companies aiming for long-term growth in international markets often benefit from working toward both, supported by strong manufacturing practices and a clear understanding of what each tender truly requires.
Sign in to leave a comment.